⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
La FDA aprueba Foundayo™ (orforglipron) de Lilly, la única pastilla GLP-1 para la pérdida de peso que puede tomarse a cualquier hora del día sin restricciones de comida o agua USA - español USA - English
prnewswire.com
LLY
Radioligand Therapy Market Expected to Surge to $10.72 Billion by 2030: Upsurge in Cancer Cases Fuelling Industry Growth at 10% CAGR
globenewswire.com
NVS
LLY
Adrenocortical Carcinoma Market Report 2026: Innovative Therapies Set to Transform the $4 Billion Adrenocortical Carcinoma Landscape
globenewswire.com
MRK
AZN
LLY
SNY
Mission BioCapital Announces Opening of $4 Million 2026 Platinum Program Contest and 2025 Platinum Ticket Investments
prnewswire.com
ABBV
LLY
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions
prnewswire.com
LLY
NVO
DIA's LIFT Series Brings Startup Pitch Competitions, Innovation Programming to Global Annual Meeting
prnewswire.com
LLY
ABBV
MRNA
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions USA - English USA - English
prnewswire.com
LLY
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
prnewswire.com
LLY
AAVantgarde appoints Philip Lao as Senior Vice President of Business Development
globenewswire.com
LLY
Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and Company, Teva Pharma, Intas Pharma, Mylan and More
globenewswire.com
LLY
AZN